Want to see TSE:RAMM full AI Analyst Report?
RAMM Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.25
Previous CloseN/A
Volume0.00
Average Volume (3M)118.29K
Market Cap
C$1.19M
Enterprise ValueC$866.77K
Total Cash (Recent Filing)C$985.37K
Total Debt (Recent Filing)C$61.30K
Price to Earnings (P/E)―
Beta-2.88
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding119,389,320
10 Day Avg. Volume262,784
30 Day Avg. Volume118,288
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.53
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Financial LeverageExtremely low debt reduces interest burden and bankruptcy risk, giving management optionality to fund operations or investments without large financing costs. Over a multi-month horizon this conservatism supports capital flexibility and resilience while the business seeks to stabilize cash flows.
Improving Cash Outflow TrendReduced negative operating and free cash flow versus prior years indicates the company has begun to slow cash burn. If sustained, this trend extends runway, lowers near-term financing dependence, and signals early operational stabilization rather than an ongoing accelerating cash drain.
Evidence Of Prior Margin ImprovementHistorical pockets of stronger gross margin imply the business can achieve better unit economics under certain mix or pricing conditions. That structural possibility means management has levers—pricing, product mix, or cost control—that could sustainably improve margins if executed consistently.
Bears Say
Sharp Revenue ContractionA significant decline in trailing revenue undermines scale and makes fixed-cost absorption harder, pressuring margins and cash generation. Over several months this shrinking top line hampers investment in growth, weakens competitive position, and increases reliance on either turnaround execution or external funding.
Persistent Heavy Operating LossesDeep, sustained negative EBIT and net margins indicate structural unprofitability: revenues do not cover operating costs. Without durable cost restructuring or meaningful revenue recovery, losses will continue to erode equity and cash, making it difficult to achieve self-sustaining operations over the medium term.
Eroded Equity And Ongoing Cash BurnMaterial decline in shareholder equity coupled with continued negative operating and free cash flow shows the balance sheet is being consumed to fund losses. Over a 2–6 month horizon, this deteriorating capital base increases financing risk and limits strategic options absent a clear reversal in profitability or external capital.
Ramm Pharma News
RAMM FAQ
What was Ramm Pharma’s price range in the past 12 months?
Ramm Pharma lowest stock price was <C$0.01 and its highest was C$0.25 in the past 12 months.
What is Ramm Pharma’s market cap?
Ramm Pharma’s market cap is C$1.19M.
When is Ramm Pharma’s upcoming earnings report date?
Ramm Pharma’s upcoming earnings report date is Sep 24, 2026 which is in 83 days.
How were Ramm Pharma’s earnings last quarter?
Ramm Pharma released its earnings results on Jun 30, 2026. The company reported -C$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.002.
Is Ramm Pharma overvalued?
According to Wall Street analysts Ramm Pharma’s price is currently Overvalued.
Does Ramm Pharma pay dividends?
Ramm Pharma does not currently pay dividends.
What is Ramm Pharma’s EPS estimate?
Ramm Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ramm Pharma have?
Ramm Pharma has 119,389,320 shares outstanding.
What happened to Ramm Pharma’s price movement after its last earnings report?
Ramm Pharma reported an EPS of -C$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ramm Pharma?
Currently, no hedge funds are holding shares in TSE:RAMM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ramm Pharma
RAMM Pharma Corp., together with its subsidiaries, operates in the pharmaceutical and medical product business in Uruguay and Poland. The company offers cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products; and pharmaceuticals, cosmetics, and nutraceutical products. It also engages in the resale of medical supplies products; and the sale of medical devices and consumables. The company was formerly known as MTC Growth Fund-I Inc. and changed its name to RAMM Pharma Corp. in October 2019. RAMM Pharma Corp. was incorporated in 1987 and is based in Toronto, Canada.
Technical Analysis
Options Prices
Currently, No data available
---